Imagion Biosystems has secured FDA clearance to proceed with its Phase 1b/2 trial of the MagSense® HER2 Imaging Agent, targeting improved detection of HER2+ breast cancer. Patient recruitment is expected to start in Q3 2026, marking a crucial step toward commercialisation.
- FDA clears IND for MagSense® HER2 Imaging Agent
- Phase 1b/2 trial recruitment to begin Q3 2026
- Trial designed to optimize dosing and diagnostic performance
- MagSense® offers radiation-free molecular MRI cancer detection
- Trial data to support AI diagnostic tool development
FDA Clearance Accelerates MagSense® Clinical Progress
Imagion Biosystems (ASX:IBX) has reached a pivotal milestone with the U.S. Food and Drug Administration granting clearance for its Investigational New Drug (IND) application for the MagSense® HER2 Imaging Agent. This green light allows the company to initiate a Phase 1b/2 clinical trial in patients with HER2-positive breast cancer, a critical step in advancing its novel MRI imaging technology toward commercial use.
The FDA's Study May Proceed Notice confirms that Imagion has met rigorous safety, manufacturing, and analytical standards. The IND submission was comprehensive, including extensive preclinical data and a detailed clinical protocol, underscoring the company's scientific discipline and operational capabilities.
Trial Design Targets Safety and Diagnostic Precision
The upcoming Phase 1b/2 trial is structured in three parts: an initial safety cohort (Part A), a dosing and imaging optimisation phase (Part B), and a larger cohort to assess diagnostic performance (Part C). Patient recruitment is anticipated to commence in the third quarter of 2026, following site activations and contracting. Interim analyses after Parts A and B will provide early insights into the agent's safety and efficacy.
This trial aims not only to confirm the diagnostic accuracy of MagSense® in detecting nodal metastases in HER2+ breast cancer but also to evaluate potential impacts on healthcare costs and patient outcomes. The integration of quantitative imaging techniques is expected to generate valuable data for developing AI-powered diagnostic tools, positioning Imagion at the intersection of molecular imaging and digital health innovation.
Addressing a Critical Unmet Need in Breast Cancer Diagnosis
HER2-positive breast cancer affects roughly 450,000 women worldwide annually and is known for its aggressive nature and high recurrence risk. Current nodal staging methods, primarily ultrasound, suffer from variable sensitivity and specificity, limiting accurate assessment of disease spread. MagSense® offers a radiation-free, molecularly targeted MRI agent that enhances tumour detection beyond traditional anatomical imaging.
Imagion's earlier Phase 1 study demonstrated that MagSense® produced clear MRI image changes distinguishing tumour-involved lymph nodes from non-involved ones. The new trial will refine dosing and imaging protocols to optimise clinical utility and safety, potentially transforming how clinicians stage and manage HER2+ breast cancer.
Leadership and Strategic Partnerships Drive Trial Execution
Dr. Eghtedari, Section Chief of Women’s Imaging at City of Hope hospital in Los Angeles, will serve as principal investigator, bringing clinical expertise and prior involvement in MagSense® studies. Imagion has also engaged strategic trial partners and begun site contracting, with preparations underway to comply fully with Good Clinical Practice and regulatory standards.
Ward Detwiler, President of Imagion’s U.S. subsidiary, highlighted the significance of the FDA clearance, noting the potential of MagSense® to revolutionise medical imaging by combining molecular precision with MRI's anatomical detail. This approval enables the company to progress from development to clinical validation, a key step toward commercialisation.
Expanding the MagSense® Platform Beyond Breast Cancer
While the current trial focuses on HER2+ breast cancer, Imagion's MagSense® technology platform has broader applications. The company has identified additional imaging agents targeting prostate and ovarian cancers, with plans to advance these candidates into IND-enabling studies as resources permit. This pipeline diversification could extend the impact of MagSense® technology across multiple cancer types.
Bottom Line?
Imagion’s FDA clearance for its Phase 1b/2 trial brings MagSense® closer to clinical validation, but the path to commercial success hinges on trial outcomes and regulatory progress beyond this milestone.
Questions in the middle?
- How will interim trial data influence the design and timing of subsequent studies?
- What competitive advantages will MagSense® hold against existing imaging modalities if trial results are positive?
- How quickly can Imagion advance its prostate and ovarian cancer imaging agents beyond preclinical stages?